

Published in final edited form as:

Genet Med. 2011 September; 13(9): 785-793. doi:10.1097/GIM.0b013e31821afc8e.

Educational needs about cancer family history and genetic counseling for cancer risk among frontline healthcare clinicians in New York City

Katarina M. Sussner, PhD, MPH¹, Lina Jandorf, MA¹, and Heiddis B. Valdimarsdottir, PhD^{1,2,3}

¹Department of Oncological Sciences, Cancer Prevention and Control, Mount Sinai School of Medicine, New York City, New York ²School of Health and Education, Reykjavik University ³Department of Psychology, University of Iceland, Iceland

Abstract

Purpose—This study investigated the educational needs of frontline healthcare clinicians about cancer family history and genetic counseling for cancer risk.

Methods—We conducted a voluntary, anonymous survey among (1) general medicine clinicians, (2) obstetrics/gynecology clinicians, and (3) nurse practitioners at Mount Sinai School of Medicine in New York City.

Results—A total of 143 clinicians completed the survey (response rate 81%). The majority of clinicians (77.5%) reported regularly completing family histories on cancer risk for their patients, but only 1.7% considered themselves "experts" in interpreting risk to make prevention, screening, and treatment recommendations. Numerous barriers to cancer family history collection were noted. More than half (55.8%) reported referring patients to genetic counseling, although only 14.3% reported confidence in their ability to make appropriate referrals. The majority reported that they would apply genetic counseling for cancer risk in their practice if they had the skills (84.9%). There was some variability found regarding specialty.

Conclusion—Despite widespread use of family histories for cancer risk, barriers remain to appropriate cancer risk management among frontline healthcare clinicians. Development of educational training programs to assist clinicians with collection of cancer family history information, interpretation, and appropriate referral along with teaching direct application of a modified form of genetic counseling for low-medium risk patients and referral of patients at genetic risk is warranted.

Keywords

cancer family history; genetic counseling

Katarina M. Sussner, PhD, MPH, Division of Cancer Prevention and Control, Department of Oncological Sciences, Mount Sinai School of Medicine, One Gustave L. Levy Place, 1425 Madison Ave, Box 1130, New York City, NY 10029. katarina.sussner@mssm.edu.

Disclosure: The authors declare no conflict of interest.

^{© 2011} Lippincott Williams & Wilkins

Understanding cancer family history is important to effectively manage cancer risk and mortality, given 25–30% of all cancers are related to a familial history of cancer (including 5–10% as hereditary or inherited predispositions within breast, ovarian, and colon cancers and another 20% by family clusters). Increasing evidence suggests that individuals considered at risk for hereditary and genetic cancer syndromes should receive genetic counseling, as genetic counseling provides individuals with a wealth of information including their personal and family risk of developing cancer; the availability of different preventive and surveillance options; and the pros and cons of undergoing genetic testing. The US Preventive Task Force 1,7 strongly recommends that all high-risk individuals with a family history suggestive of hereditary breast and ovarian cancer undergo genetic counseling. Similarly, the revised Bethesda Guidelines and National Comprehensive Cancer Center Network clinical practice guidelines provide a framework for identifying individuals who should undergo genetic counseling and testing for hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis. 8,9

Despite the benefits of genetic counseling for hereditary cancer risk, research suggests that frontline healthcare clinicians who have most frequent contact with at-risk patients may have very limited information about appropriate risk management including referrals for genetic counseling based on collection and interpretation of cancer family history information. In fact, research suggests that family history is the most important tool for diagnosis and risk assessment management in medical genetics, even though translational education in this area to date has been extremely unsophisticated and limited. ¹⁰ Family history is considered a cornerstone to screening and managing common diseases and in particular cancer, with approximately 20% of primary care patients having family histories which would place them at increased risk for cancer. 11,12 However, surprisingly, collection of family history in the primary care setting has been grossly underused to date. ¹³ Barriers to collection of family history are both patient and clinician related. Known patient-related barriers to collection of family history include low knowledge and lack of awareness about relatives' health information, inaccuracies in patient recall, poor communication, and language-related, cultural, and education-related factors, which may impede collection of an accurate family history. For example, although a survey of patients in 2004 found that 96% of respondents believed knowledge of family history was "somewhat" or "very important," <1/3 of patients actually collected health information from relatives. 14 From the clinicians' end, known barriers include inadequate time to collect family history due to short office visits, lack of reimbursement for collection, and the lack of clear guidelines to assess low, moderate, and high-risk patients. 10,12,13,15-18

Due to the increasingly influential role frontline healthcare clinicians will inevitably fill for genetic services for cancer risk in a renewed era which focuses on preventive care as part of healthcare reform, it is imperative to understand the current state of clinical practice related to cancer family history collection and appropriate cancer risk management including genetic counseling referral among these clinicians. We conducted a brief, voluntary, and anonymous survey about the educational needs of frontline healthcare clinicians (defined here as including general medicine clinicians, obstetrics/gynecology [ob/gyn] clinicians, and nurse practitioners) about cancer family history and genetic counseling for cancer risk. The

purpose of this survey was to identify needs of frontline healthcare clinicians in this area to inform the development and design of future educational interventions and programs.

MATERIALS AND METHODS

Eligibility criteria for participating in the survey included any clinicians who were currently attending the Grand Rounds session of their respective Departments at Mount Sinai School of Medicine in New York City (NYC) including (1) general medicine; (2) ob/gyn, and (3) nurse practitioners. A trained Research Assistant (RA) attended each Department's Grand Rounds session at a specific date and time, with prior permission of the head of each Grand Rounds Department. The trained RA made a brief announcement at the beginning of the session about the purpose of the survey, handed out surveys, and announced that she would collect surveys at the end of the Grand Rounds session. At the end of the session, the anonymous surveys were returned by the RA to a stored/locked location in the principal investigator's office. The survey responses were entered into a password-protected electronic computer file.

The study was anonymous and had no risk to the subject's employability, reputation, or financial standing. To demonstrate whether there is a need for this information among frontline healthcare clinicians, we purposely chose to conduct this study among general medicine clinicians, ob/gyn clinicians, and nurse practitioners. However, there were no biases in terms of the groups of respondents expected to be more open to or interested in providing genetic counseling or referrals, thus why the proposed needs assessment was deemed critical. Individuals who chose to participate in the survey read a short statement before beginning the survey acknowledging that they were consenting to participating in the anonymous survey and that they could stop their participation at anytime. Individuals were informed that this survey was being completed for research purposes to inform the development of a future educational training for nurses, ob/gyn physicians or practitioners physicians, and general practitioners about cancer family history collection and genetic counseling for cancer risk. No individuals received compensation for completing the survey. The study was approved by the Mount Sinai School of Medicine Institutional Review Board.

Needs assessment survey

The 12-item needs assessment survey included questions related to (1) current state of the cancer family history collection in clinical practice (including how often updated, what kinds of information is included, level of perceived skill interpreting cancer risk based on family history information, and barriers to collecting cancer family history); (2) current state of referrals for genetic counseling and testing for cancer risk in clinical practice (including perceived level of confidence in making appropriate referrals and whether clinicians conduct their own genetic counseling and related perceived level of skill) and influence of advertisements from genetic testing companies; and (3) interest in educational tools and programs to assist with collection of cancer family history information and application of genetic counseling in clinical practice (including importance placed and application of genetic counseling in clinical practice, level of motivation to learn genetic counseling, and interest in attending training workshop for genetic counseling).

Statistics

Descriptive statistics was conducted to measure the frequency of participant responses to each item. Statistical comparisons were calculated to see whether there were any measurable differences on survey items between the three main groups surveyed (1) ob/gyn, (2) general medicine, and (3) nurse practitioners. Logistic regression analyses were calculated (reporting associated odds ratios [ORs], 95% confidence intervals [CI], and *P* values in the results) for survey items with dichotomous responses. Linear regression analyses were performed (reporting associated beta coefficients, standard errors (SEs), and *P* values in the results) on survey items with linear responses. All statistical programming was completed with SAS 9.1.3 statistical software.

RESULTS

Sample

A total of 143 clinicians (40% ob/gyn, 21% nurse practitioners, 21% general medicine, and 18% other medical specialties) completed the survey, with a response rate of 81%. For the purposes of making meaningful comparison between clinical practice groups, clinicians who identified themselves as "other medical specialties" were not included in these comparisons.

Current state of cancer family history collection in clinical practice

Table 1 reports survey results related to the current state of cancer family history collection in clinical practice.

Collection of cancer family history information—Although the majority (77.5%) reported regularly completing family histories/pedigrees on cancer risk on their patients, only a quarter of respondents (25.9%) included several key components of a minimum adequate cancer family history (first- and second-degree relatives on both maternal and paternal side, type of cancer, and age at time of cancer diagnosis). 18 Most clinicians reported updating these family histories once a year (57.4%), with the next largest group never updating family histories (22.2%). Less than half (43.4%) of clinicians reported including family history on the paternal side in family histories/pedigrees, family history on the maternal side (48.3%), second-degree relatives (40.6%), or age at time of cancer diagnosis (43.4%). Ob/gyn clinicians had more than six times the odds of reporting the collection of cancer family history information compared with general medicine clinicians and nurse practitioners (OR = 6.3, 95% CI = 2.2-18.2, P = 0.0006) and had more than three times the odds of collecting all the necessary information in the family histories collected (OR = 3.3, 95% CI = 1.4 - 7.8, P = 0.007). Nurse practitioners had lower odds of regularly completing family histories on cancer risk for their patients (OR = 0.1, 95% CI = 0.4–0.3, P < 0.0001) and lower odds of collecting all the necessary kinds of information required in the family histories (OR = 0.3, 95% CI = 0.1-0.9, P = 0.05) compared with ob/gyn and general medicine clinicians.

Perceived skill in interpreting cancer risk based on family history information

—Only 1.7% of clinicians considered themselves "experts" in terms of their perceived level of skill in interpreting cancer risk based on family history information and subsequent

prevention, screening, and treatment recommendations. Ob/gyn clinicians reported a higher level of perceived skill related to interpreting cancer risk compared with general medicine clinicians and nurse practitioners ($\beta = 0.4$, SE = 0.2, P = 0.03). Nurse practitioners report lower levels of skill in interpreting cancer risk compared with the other two groups ($\beta = -0.7$, SE = 0.3, P = 0.01).

Perceived barriers to collection of cancer family history—Main perceived barriers to collecting cancer family history and risk information included lack of time on part of the clinician to collect such information (44.8%) and lack of patient knowledge about cancer family history (44.8%). Other barriers included low perceived ability to identify low, moderate, and high-risk cases and provide appropriate risk management (29.4%) and language and cultural barriers with their patients related to collection of cancer family history and risk information (25.2%). Ob/gyn clinicians had higher odds of reporting a lack of time to collect cancer family history information (OR = 3.8, 95% CI = 1.8-8.2, P =0.0006) and lack of time to interpret information and provide appropriate risk management and counseling (OR = 2.7, 95% CI = 1.2-6.3, P = 0.02) compared with general medicine clinicians and nurse practitioners. Nurse practitioners had lower odds of reporting a lack of patient knowledge about cancer family history (OR = 0.09, 95% CI = 0.03-0.3, P = 0.0002), a lack of time to collect cancer family history information (OR = 0.1, 95% CI = 0.04–0.4, P = 0.0002), and a lack of time to interpret information and provide appropriate risk management and counseling (OR = 0.06, 95% CI = 0.008, 0.5, P = 0.0007) compared with ob/gyn and general medicine clinicians.

Current state of referrals for genetic counseling and testing in clinical practice and influence of advertisements from genetic testing companies

Table 2 reports the results related to the current state of referrals for genetic counseling and testing in clinical practice and the influence of advertisements from genetic testing companies.

Referral for genetic counseling and testing for cancer risk—Only 16.7% of clinicians reported ordering genetic tests directly for cancer risk. Despite the widespread use of completing family histories on cancer risk, only 44.1% of clinicians reported that they refer patients to genetic counseling for cancer risk, with only 14.3% of clinicians reporting that they felt "confident" or "very confident" in their ability to make appropriate referrals. Ob/gyn clinicians had six times the odds of reporting the ordering of genetic tests directly (OR = 6.0, 95% CI = 1.9 - 19.1, P = 0.003), had eight times the odds of referring patients to genetic counseling for risk (OR = 8.1, 95% CI = 3.5-18.9, P < 0.0001), and reported higher confidence in their ability to make appropriate referrals for genetic counseling for cancer risk ($\beta = 1.1$, SE = 0.2, P < 0.0001) compared with general medicine clinicians and nurse practitioners. Nurse practitioners had lower odds of referring patients to genetic counseling for cancer risk compared with ob/gyn and general medicine clinicians (OR = 0.1, 95% CI = 0.03-0.4, P=0.0005) and reported less confidence in their ability to make appropriate referrals ($\beta = -1.5$, SE = 0.4, P = 0.0002). General medicine clinicians had lower odds of referring patients to genetic counseling compared with ob/gyn and nurse practitioners (β = 0.4, 95% CI = 0.2-0.9, P = 0.05).

Influence of advertising from genetic testing companies in clinical practice—

Approximately 23.6% of clinicians reported receiving advertisements from genetic testing companies about their products for cancer risk mutations. The majority of clinicians (66.7%) believed these advertisements did not influence their decision to order genetic tests for patients at all. Ob/gyn clinicians had close to eight times the odds of receiving advertisements compared with general medicine and nurse practitioners (OR = 7.9, 95% CI = 2.7-22.6, P = 0.0001). General medicine clinicians had lower odds of receiving advertisements (OR = 0.2, 95% CI = 0.07-0.9, P = 0.03) compared with ob/gyn and nurse practitioners, whereas nurse practitioners had statistically significant lower odds of receiving advertisements compared with ob/gyn and general medicine clinicians (OR = 0.2, 95% CI = 0.04-0.8, P = 0.02).

Genetic counseling for cancer risk

Approximately 21.6% of clinicians reported that they currently do their own genetic counseling for cancer risk with their patients. None of these clinicians considered themselves an "expert" in terms of their perceived level of skill related to genetic counseling. Meanwhile, 26.7% reported their perceived level of skill as "novice" ("1" on a scale of "1–5") and 30% as "2" on a scale of "1–5." Ob/gyn clinicians had higher odds of doing their own genetic counseling for cancer risk compared with general medicine clinicians and nurse practitioners (OR = 2.7, 95% CI = 1.1–6.9, P = 0.04).

Interest in educational tools for assisting collection of cancer family history and programs to assist with collection of cancer family history information and application of genetic counseling in clinical practice

Table 3 reports results related to interest in educational tools and programs to assist with collection of cancer family history information and application of genetic counseling in clinical practice.

Interest in educational tools—Most clinicians were interested (64.1% reporting "interested" to "extremely interested") in an interactive educational tool for completing family histories for cancer risk to assist clinicians in interpreting risk level and communicating appropriate risk recommendations and a tool for patients' use (66.9% reporting "interested" to "extremely interested"). General medicine clinicians reported less interest in a tool for patients' use compared with ob/gyn clinicians and nurse practitioners (β =-0.6, SE = 0.2, P = 0.02).

Importance of genetic counseling and interest in training for genetic

counseling—Most clinicians (61.9%) believed it would be important to use genetic counseling in their practice if they felt proficient. In fact, 84.9% said they would apply genetic counseling in their current work setting if they had the skills, and 76.2% were interested in attending a training workshop on genetic counseling for cancer risk with continuing medical education credits available. General medicine clinicians placed lower importance on genetic counseling for cancer risk in their practice ($\beta = -0.9$, SE = 0.21, P < 0.0001) and reported lower motivation to learn genetic counseling for cancer risk ($\beta = -0.8$, SE = 0.2, P = 0.0002) compared with ob/gyn clinicians and nurse practitioners. Ob/gyn

clinicians placed more importance on genetic counseling for cancer risk in their practice (β = 0.7, SE = 0.2, P = 0.0003) and had close to three times the odds of being interested in attending a training workshop on genetic counseling for cancer risk compared with general medicine clinicians and nurse practitioners (OR = 2.7, 95% CI = 1.1–6.6, P = 0.03).

DISCUSSION

Study results inform the literature by documenting the current state of cancer family history collection, referral for genetic counseling practices, and related educational needs of frontline healthcare clinicians in NYC. As we enter the era of healthcare reform which will place a renewed focus on preventive care, such information is particularly timely and relevant as there will be an unprecedented demand on clinicians to understand how to appropriately manage cancer risk. Results found that despite widespread collection of cancer family history, barriers remained related to the lack of completeness of family histories, low perceived skill in the ability to interpret family histories, lack of time on part of the practitioner to collect cancer family history information, and lack of patient knowledge about cancer family history and concerns about ability to identify low, moderate, and high-risk cases and provide appropriate risk management. Although many of these barriers have been previously described in the literature, 10,12,13,15–18 this study advances our understanding one step further by uniquely identifying specific educational and training needs of frontline healthcare clinicians who will increasingly face pressure to manage cancer risk in their patients.

As previous research shows, complete and accurate family histories are critical to making appropriate referrals for genetics services and clear guidelines for physicians. ¹⁹ In line with study findings, research describes how lack of complete family histories may be related to limited knowledge about cancer genetics among clinicians. ^{20,21} Comprehensiveness and quality of family histories collected by clinicians may be limited by failure to include other information deemed critical to genetic risk assessment such as information on second-degree relatives and age at time of diagnosis. Furthermore, as family history is dynamic and changing, it is recommended that family history information should be updated regularly, ²² a recommendation not met by almost a quarter of respondents in this study. In fact, results are in accordance with previous literature, which has found that information on second-degree relatives and age at diagnosis are often missing or not updated frequently. ^{12,23,24} It is, thus, advised that educational trainings for clinicians about cancer family history collection incorporate not only which components should be included in a family history but also include specific instruction on the importance of updating these tools at least once a year to ensure quality.

Study results related to the low perceived skill in interpreting cancer risk among frontline healthcare clinicians fall in line with previous research documenting low ability to assign risk. In theory, guidelines should be used by physicians to correctly estimate categories of patient risk: low, moderate, or high and make appropriate referrals and screening and prevention-related management decisions based on this risk. However, a recent study found that primary care physicians' ability to correctly assign risk was low, even in cases where they reported high levels of confidence in their ability to assign risk; specifically, half of

primary care physicians incorrectly assigned a high-risk categorization to a low-risk case.²⁵ In another study using unannounced standardized (simulated) patients, satisfaction with physician communication was higher for moderate risk cases compared with high-risk case,²⁶ highlighting that many physicians are unprepared to address complex high-risk scenarios. Results suggest that educational training programs designed for frontline healthcare clinicians should focus on increasing the ability of clinicians to correctly identify risk level and make appropriate risk management recommendations (surveillance, screening, and referral for counseling).

Study results underscore a low perceived ability of clinicians to make appropriate referrals to genetic counseling, specifically. Previous literature demonstrates problems of underreferral for genetic counseling and a lack of identification of patients at highest risk, correlated with insufficient collection of family history, risk assessment, and documentation by medical staff, as well as lack of confidence by clinicians in managing genetic counseling. Sweet et al. ¹⁶ examined the extent to which cancer family history completed by physician matched information entered by patients. Results found that many patients had little or no family history documented in medical records and rarely updated beyond the first visit. Most critically, physician-completed information failed to confirm patient information, particularly with patients assigned to a high-risk category, resulting in low referral for genetic counseling by physicians. Of 69 high-risk patients, only 20% had a notation acknowledging high risk in their medical record from their physician. Of those with the notation, only 50% were referred to genetic counseling.

Study results found that of those clinicians who self-report doing their own genetic counseling, clinicians' perceived ability to conduct such counseling is low. Such results are in agreement with previous findings from a nationally representative survey documenting that only a small proportion of physicians felt qualified to provide genetic counseling to their patients directly (29%). However, given that the availability of genetic counseling services may be constrained in some communities, 27,28 compounded by an increasing number of individuals seeking genetic counseling and the increased burden of previously underserved patients entering the system by healthcare reform, 29 there remains the opportunity for clinicians to learn how to conduct a modified or shortened form of genetic counseling through educational trainings to make surveillance and screening recommendations to their patients.

In fact, study results greatly contribute to this body of literature by demonstrating an overwhelming interest in educational tools and programs for clinicians to assist with collection of cancer family history information and to help apply genetic counseling in clinical practice. The desire of clinicians to apply genetic counseling in their work setting themselves was strong, along with the need to feel more confident in having the skills to do so. Additionally, interest in training workshops for clinicians focused on gaining genetic counseling skills was high. Study results documented the need and usefulness of educational tools designed both for patients' and practitioners' dual use. In recent years, several primarily patient-based computerized tools have been developed to assist patients with collecting cancer family history and thereby facilitate more appropriate referral and management for genetic services for cancer risk by clinicians. ^{13,16,30–35} Through online

websites, touch-screen kiosk, and tablet-based formats, the goal of the majority of these tools has been to provide printout pedigrees collected outside of the regular clinician visit for patients to bring to their physicians to help communicate and manage cancer risk. However, to our knowledge, the majority of these tools to date have not directly involved educational training of frontline healthcare clinicians in how to actually interpret patient pedigrees, calculate risk calculations, and/or provide appropriate cancer risk management recommendations to patients. Furthermore, none of these tools teach clinicians how to do appropriate genetic and risk management counseling for low-medium risk women and appropriate referrals to genetic counseling services for those at genetic risk, which is of clear interest to clinicians based on our study results. For this reason, future research should work toward the development of training programs to overcome barriers to appropriate cancer risk management, including educating frontline healthcare clinicians in direct application and interpretation of such computerized tools and instructing patients how to complete patientbased tools. Both these efforts would help substantially reduce the amount of time and knowledge required on the part of the clinician to complete a pedigree by hand, along with help improve the comprehensiveness and quality of family history collected. Another useful training area would be assisting clinicians to conduct a modified or abbreviated form of genetic counseling for their low-medium risk patients to provide appropriate risk management recommendations including surveillance and screening. In fact, as the number of self-referred patients to genetic services increases, research shows that greater emphasis should be on the clinicians' ability to not only provide appropriate referrals but also, perhaps more importantly, be able to effectively communicate and reassure patients who are not at high risk, providing reassurance in place of referral 36-38 and oftentimes dissuading low-risk patients from counseling and testing.³⁹ Meanwhile, at the same time, training clinicians in how to manage and appropriately refer high-risk patients directly to genetic counseling would be critical.

Finally, a number of statistically significant differences between clinician groups found in this study point to the need for different educational trainings based on clinical practice area. Ob/gyn clinicians had higher odds compared with general medicine and nurse practitioners of completing family histories on their patients, including the necessary information on these histories, ordering genetic tests directly, receiving advertisements from genetic testing companies, referring for genetic counseling, doing their own genetic counseling, and being interested in attending a training for genetic counseling. Ob/gyn clinicians also reported higher perceived levels of skill in interpreting cancer risk, confidence making appropriate referrals for genetic counseling, and more importance placed on genetic counseling. Recent literature has shown that the majority of ob/gyn residents regularly complete family histories in their obstetrics practice (90%) and cancer family histories in their gynecology practice (80%), 76% indicating a desire for more information and education about hereditary cancer and genetic testing. ⁴⁰ In another recent study, however, only two thirds of ob/gyn clinicians felt "partially qualified" to manage genetic counseling for breast and gynecologic genetic screening, with the remainder feeling "not qualified." ⁴¹ Previous research has documented differences in knowledge and experience with breast cancer genetic testing between medical oncologists, internists, and ob/gyn clinicians; for example, only 21% of ob/gyns correctly answered all knowledge questions compared with 13% of internist and 40% of

oncologists. 42 However, to the authors' knowledge, no previous research has compared general medicine, ob/gyn, and nurse practitioners specifically to date. It is possible that ob/gyn clinicians are more likely to encounter discussions related to these topics given that women may be more likely to discuss issues related to their reproductive organs with their ob/gyn compared with their general medicine clinician or nurse practitioner. In addition, the role of ob/gyn clinicians in identifying hereditary cancers among women may be particularly critical given many women are exclusively cared for by their ob/gyn clinician. 40 It remains unclear whether ob/gyn clinicians have actually experienced more training in making appropriate referrals and managing cancer risk compared with other clinician groups. Given the more limited role nurse practitioners have in medical decisions in general, it was not particularly surprising that nurse practitioners had lower odds of completing family histories, of referring for genetic counseling and reported less skill in interpreting cancer risk and less confidence in ability to make appropriate referrals. However, it may be critical that nurse practitioners assume a larger role in the care and management of cancer risk, as primary care faces increased demands underscoring the need for training of this group. Finally, as study results documented that general medicine clinicians had lower odds of referring for genetic counseling, reported less interest in educational tools for patients' use, less importance on genetic counseling in their practice, and less motivation to learn genetic counseling, educational efforts to train clinicians may want to target efforts specifically to this group, particularly to focus on training to recognize and refer appropriate patients.

Study limitations

There are a few study limitations which should be noted. First, by virtue of using a selfadministered survey design, this study only reported clinicians' perceived practices regarding cancer family history collection and genetic counseling for cancer risk. We did not evaluate actual clinicians' practices or investigate patient records to see whether reported practices matched those in actual practice, which should be undertaken in future research. Second, given this was a voluntary survey, it is possible that the study is biased by including only those individuals who are interested in cancer family history and genetic counseling. In other words, some percentages could be inflated due to more interest in this sample. However, as the response rate was very high (81%), potential selection bias of participants is less likely to be a concern. Third, this study did not collect sociodemographic information on survey participants, which does not make it possible to analyze possible differences such as years' training, ethnicity of clinician, age, or gender. Fourth, as we wanted to collect information pertinent to cancer family history across cancers and not just breast cancer alone (BRCA1/2), we did not include ethnicity/ancestry as a key component to be included as part of routine cancer family history collection. ¹⁸ However, it would be useful to determine the extent to which ethnicity/ancestry is noted in family histories in future studies. Finally, as this study only investigated these specific practice groups at one particular hospital in NYC, study results may not be generalizable to other clinician groups or outside of this particular hospital in NYC. By administering the survey at Grand Rounds sessions, however, in which a diverse collection of clinicians in a particular practice group are in attendance (residency clinicians and attending clinicians), we hoped to capture a wide range of experiences and years of clinical training, which would make the results more applicable to a greater audience.

CONCLUSIONS

Ultimately, study results capture the current state of cancer family history collection, referrals for genetic counseling, and related educational needs among a diverse group of frontline healthcare clinicians (including general medicine, ob/gyn, and nurse practitioners) in NYC. Despite the widespread use of family histories on cancer risk for patients, there remain barriers to appropriate cancer risk management including referral for genetic counseling among these groups. The development of educational tools and training programs to assist clinicians with collection of cancer family history information, interpretation, and appropriate referral along with teaching direct application of a modified form of genetic counseling for low-medium risk patients and referral of patients at genetic risk is warranted.

ACKNOWLEDGMENTS

The authors acknowledge the contribution of Research Assistant, Ms. Elizabeth Zaita, for her assistance in collecting data for this study.

REFERENCES

- Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25:1329–1333. [PubMed: 17416853]
- Kohlmann, W.; Gruber, SB. Hereditary non-polyposis colon cancer. In: Pagon, RA.; Bird, TC.;
 Dolan, CR.; Stephens, K., editors. GeneReviews (Internet). Seattle, WA: University of Washington,
 Seattle; 2005. p. 1993-2004.
- 3. Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994; 3:121–125. [PubMed: 8199592]
- 4. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement updated: genetic testing for cancer susceptibility. Clin Oncol. 2003; 21:2397–2406.
- 5. Hall MJ, Olopade OI. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006; 24:2197–2203. [PubMed: 16682739]
- 6. Olopade OI. Genetics in clinical cancer care: a promise unfulfilled among minority populations. Cancer Epidemiol Biomarkers Prev. 2004; 13:1683–1686. [PubMed: 15533893]
- 7. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005; 23:1656–1663. [PubMed: 15755973]
- 8. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96:261–268. [PubMed: 14970275]
- 9. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010; 8:8–61. [PubMed: 20064289]
- Rich EC, Burke W, Heaton CJ, et al. Reconsidering the family history in primary care. J Gen Intern Med. 2004; 19:273–280. [PubMed: 15009784]
- 11. Frezzo TM, Rubinstein WS, Dunham D, Ormond KE. The genetic family history as a risk assessment tool in internal medicine. Genet Med. 2003; 5:84–91. [PubMed: 12644777]
- 12. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA. 2004; 292:1480–1489. [PubMed: 15383520]
- 13. Carmona RH, Wattendorf DJ. Personalizing prevention: the U.S. Surgeon General's Family History Initiative. Am Fam Physician. 2005; 71:36–39. [PubMed: 15663022]
- Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ. Developing Family Healthware, a family history screening tool to prevent common chronic diseases. Prev Chronic Dis. 2009; 6:A33. [PubMed: 19080039]

 Acton RT, Burst NM, Casebeer L, et al. Knowledge, attitudes, and behaviors of Alabama's primary care physicians regarding cancer genetics. Acad Med. 2000; 75:850–852. [PubMed: 10965867]

- Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002; 20:528–537. [PubMed: 11786583]
- 17. Wood ME, Stockdale A, Flynn BS. Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract. 2008; 25:334–340. [PubMed: 18765407]
- 18. Qureshi, N.; Wilson, B.; Santaguida, P. AHRQ No. 08-E001. Agency for Healthcare Research and Quality; 2007. Collection and use of cancer family history in primary care. Evidence report/technology assessment.
- 19. Freedman AN, Wideroff L, Olson L, et al. US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A. 2003; 120A:63–71. [PubMed: 12794694]
- Wideroff L, Freedman AN, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003; 12:295–303. [PubMed: 12692103]
- 21. Burke W, Culver J, Pinsky L, et al. Genetic assessment of breast cancer risk in primary care practice. Am J Med Genet A. 2009; 149A:349–356. [PubMed: 19208375]
- Ready K, Arun B. Clinical assessment of breast cancer risk based on family history. Natl Compr Canc Netw. 2010; 8:1148–1155.
- Flynn BS, Wood ME, Ashikaga T, Stockdale A, Dana GS, Naud S. Primary care physicians' use of family history for cancer risk assessment. BMC Fam Pract. 2010; 11:45. [PubMed: 20525302]
- 24. Murff HJ, Greevy RA, Syngal S. The comprehensiveness of family history assessments in primary care. Comm Genet. 2007; 10:174–180.
- Bethea J, Qureshi N, Drury N, Guilbert P. The impact of genetic outreach education and support to primary care on practitioner's confidence and competence in dealing with familial cancers. Community Genet. 2008; 11:289–294. [PubMed: 18493127]
- Culver JO, Bowen DJ, Reynolds SE, Pinsky LE, Press N, Burke W. Breast cancer risk communication: assessment of primary care physicians by standardized patients. Genet Med. 2009; 11:735–741. [PubMed: 19661809]
- 27. Green MJ, Peterson SK, Baker MW, et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA. 2004; 292:442–452. [PubMed: 15280342]
- 28. National Society of Genetic Counselors. Familial cancer risk counseling special interest group directory. Wallingford, PA: National Society of Genetic Counselors; 2003.
- American Reinvestment and Recovery Act of 2009; Public Law 111–5 of the 111th United States Congress; 2009.
- 30. Skinner CS, Rawl SM, Moser BK, et al. Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. J Gen Intern Med. 2005; 20:360–365. [PubMed: 15857495]
- Buchanan AH, Skinner CS, Rawl SM, et al. Patients' interest in discussing cancer risk and risk management with primary care physicians. Patient Educ Couns. 2005; 57:77–87. [PubMed: 15797155]
- 32. O'Neill, SM.; Starzyk, EJ.; Kattezham, RA.; Rubinstein, WS. Comparison of Family HealthwareTM and physicians' family history documentation among 1124 patients. Evanston, IL: Dept Medical Genetics, Evanston NW Healthcare; 2008.
- 33. Braithwaite D, Sutton S, Smithson WH, Emery J. Internet-based risk assessment and decision support for the management of familial cancer in primary care: a survey of GPs' attitudes and intentions. Fam Pract. 2002; 19:587–590. [PubMed: 12429659]
- 34. Simon C, Acheson L, Burant C, et al. Patient interest in recording family histories of cancer via the Internet. Genet Med. 2008; 10:895–902. [PubMed: 19092442]
- 35. Centers for Disease Control. Awareness of family health history as a risk factor for disease— United States, 2004. MMWR Morb Mortal Wkly Rep. 2004; 53:1044–1047. [PubMed: 15538320]

36. Grande GE, Hyland F, Walter FM, Kinmonth AL. Women's views of consultations about familial risk of breast cancer in primary care. Patient Educ Couns. 2002; 48:275–282. [PubMed: 12477612]

- 37. Emery J, Lucassen A, Murphy M. Common hereditary cancers and implications for primary care. Lancet. 2001; 358:56–63. [PubMed: 11454400]
- 38. Emery J, Rose P. Expanding the role of the family history in primary care. Br J Gen Pract. 1999; 49:260–261. [PubMed: 10736900]
- 39. White DB, Bonham VL, Jenkins J, Stevens N, McBride CM. Too many referrals of low-risk women for BRCA1/2 genetic services by family physicians. Cancer Epidemiol Biomarkers Prev. 2008; 17:2980–2986. [PubMed: 18990739]
- 40. Ready KJ, Daniels MS, Sun CC, Peterson SK, Northrup H, Lu KH. Obstetrics/ gynecology residents' knowledge of hereditary breast and ovarian cancer and lynch syndrome. J Cancer Educ. 2010; 25:401–404. [PubMed: 20186516]
- 41. Menzin AW, Anderson BL, Williams SB, Schulkin J. Education and experience with breast health maintenance and breast cancer care: a study of obstetricians and gynecologists. J Cancer Educ. 2010; 25:87–91. [PubMed: 20101531]
- 42. Doksum T, Bernhardt BA, Holtzman NA. Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA genetic testing? Genet Med. 2003; 5:99–105. [PubMed: 12644779]

Table 1

Current state of cancer family history collection in clinical practice

| | Participant responses, N (%) | Statistically significant differences between clinical practice ${\rm groups}^a$ | | | |
|--|----------------------------------|--|----------------------------------|------------------------------------|--|
| Survey item | | Ob/Gyn vs. Gen Med and NPs | Gen Med vs. Ob/Gyn and NPs | NPs vs. Ob/Gyn and Gen Med | |
| Do you regularly complete family histories/ | pedigrees on cancer risk for you | r patients? | | | |
| Yes | 110 (77.5) | 6.3 (2.2–18.2); <i>P</i> = 0.0006 | NS | 0.1 (0.04–0.3); <i>P</i> < 0.0001 | |
| No | 32 (22.5) | | | | |
| If "yes," how often do you update these fam | ily histories/pedigrees on cance | r risk? | | | |
| Never | 24 (22.2) | NS | NS | NS | |
| Once a year | 62 (57.4) | | | | |
| Several times a year | 12 (11.1) | | | | |
| At every visit, regardless of purpose of visit | 10 (9.3) | | | | |
| If "yes," which of the following kinds of inf | ormation do these family histor | ies/pedigrees routinely inc | clude (all that apply |)? | |
| First-degree relatives | 99 (69.2) | 3.9 (1.7–9.2); <i>P</i> = 0.002 | NS | 0.2 (0.1–0.5); <i>P</i> = 0.002 | |
| Second-degree relatives | 58 (40.6) | 3.1 (1.5–6.7); <i>P</i> = 0.004 | NS | 0.3 (0.1–0.9); <i>P</i> = 0.02 | |
| Type of cancer | 88 (62.4) | 3.9 (1.7–8.6); <i>P</i> = 0.0009 | NS | 0.2 (0.01–0.4); <i>P</i> < 0.0001 | |
| Age at time of diagnosis | 62 (43.4) | NS | NS | 0.2 (0.1–0.6); <i>P</i> = 0.003 | |
| Family history maternal | 69 (48.3) | NS | NS | 0.40 (0.2–0.9); <i>P</i> = 0.04 | |
| Family history paternal | 62 (43.4) | NS | NS | 0.40 (0.2–0.9); <i>P</i> = 0.03 | |
| All above information | 37 (25.9) | 3.3 (1.4–7.8); <i>P</i> = 0.007 | NS | 0.3 (0.1–0.9); <i>P</i> = 0.05 | |
| If "yes," how would you rate your level of si information you collect and subsequent prev | | | | history/pedigree | |
| 1 = novice | 13 (11.3) | 0.4 (SE = 0.2); P = 0.03 | NS | -0.7 (SE = 0.3); <i>P</i> = 0.01 | |
| 2 | 38 (33.0) | | | | |
| 3 | 43 (37.4) | | | | |
| 4 | 19 (16.5) | | | | |
| 5 = expert | 2 (1.7) | | | | |
| Which of the following barriers to collecting | g cancer family history and risk | information do you currer | ntly face in your pra | actice (all that apply)? | |
| Ability to identify low, moderate high risk cases and provide appropriate risk management | 42 (29.4) | NS | NS | NS | |
| Language and cultural barriers with patients | 36 (25.2) | NS | NS | NS | |
| Lack of patient knowledge about cancer family history | 64 (44.8) | NS | 2.9 (1.2–6.8); P = 0.02 | 0.09 (0.03–0.3); <i>P</i> = 0.0002 | |
| Lack of time for practitioner to collect cancer family history information | 64 (44.8) | 3.8 (1.8–8.2); <i>P</i> = 0.0006 | NS | 0.1 (0.04–0.4); <i>P</i> = 0.0002 | |

| | Participant responses, $N\left(\% ight)$ | Statistically significant differences between clinical practice ${\rm groups}^a$ | | |
|--|--|--|----------------------------------|-------------------------------------|
| Survey item | | Ob/Gyn vs. Gen Med and NPs | Gen Med vs. Ob/Gyn and NPs | NPs vs. Ob/Gyn and Gen Med |
| Lack of time for practitioner to interpret information, provide appropriate risk management and counseling | 39 (27.3) | 2.7 (1.2–6.3); <i>P</i> = 0.02 | NS | 0.06 (0.008–0.5); <i>P</i> = 0.0007 |

 $^{^{}a}$ Reporting odds ratios (95% confidence intervals) and p values for dichotomous variables. Reporting beta coefficient (standard error) and p values for continuous variables.

NS, not significant; Gen Med, general medicine; NP, nurse practitioner.

Table 2

Current state of referrals for GC and GT in clinical practice and influence of advertisements from GT companies

| | | Statistically significant differences between clinical practice groups $\!\!^a$ | | | |
|-----------------------------|------------------------------|---|-----------------------------------|-----------------------------------|--|
| | Participant responses, N (%) | Ob/Gyn vs. Gen Med and NPs | Gen Med vs. Ob/Gyn and NPs | NPs vs. Ob/Gyn and Gen Med | |
| Do you currently order gen | etic tests directly for ye | our patients for cancer risk? | | | |
| Yes | 23 (16.7) | 6.0 (1.9–19.1); $P = 0.003$ | NS | NS | |
| No | 115 (83.1) | | | | |
| Do you directly receive adv | vertisements from gene | tic testing companies about the | ir products available for can | cer risk mutations? | |
| Yes | 33 (23.6) | 7.9 (2.7–22.6); $P = 0.0001$ | 0.2 (0.07-0.9); P = 0.03 | 0.2 (0.04-0.8); P = 0.02 | |
| No | 107 (76.4) | | | | |
| If "yes," how much do thes | se advertisements influe | ence your decision to order gen | etic tests for your patients? | | |
| 1 = not at all | 24 (66.7) | NS | NS | NS | |
| 2 = somewhat | 12 (33.3) | | | | |
| 3 = a lot | 0 (0) | | | | |
| Do you currently refer your | r patients to genetic cou | inseling for cancer risk? | | | |
| Yes | 60 (44.1) | 8.1 (3.5–18.9); <i>P</i> < 0.0001 | 0.4 (0.2-0.9); P = 0.05 | 0.1 (0.03–0.4); <i>P</i> = 0.0005 | |
| No | 76 (55.9) | | | | |
| If "yes," how confident do | you feel about your ab | ility to make appropriate referr | als for genetic counseling fo | r cancer risk? | |
| 1 = not at all confident | 7 (11.1) | 1.1 (SE = 0.2); $P < 0.0001$ | NS | -1.5 (SE = 0.4); $P = 0.0002$ | |
| 2 = somewhat confident | 26 (41.3) | | | | |
| 3 = confident | 21 (33.3) | | | | |
| 4 = very confident | 7 (11.1) | | | | |
| 5 = extremely | 2 (3.2) | | | | |
| Do you currently do your o | wn genetic counseling | for cancer risk? | | | |
| Yes | 30 (21.6) | 2.7 (1.1–6.9); <i>P</i> = 0.04 | NS | NS | |
| No | 109 (78.4) | | | | |
| If "yes" how would you rat | te your level of skill rel | ated to genetic counseling for | cancer risk $(1 = novice, 5 = 6)$ | expert)? | |
| 1 = novice | 8 (26.7) | NS | NS | NS | |
| 2 | 9 (30.0) | | | | |
| 3 | 8 (26.7) | | | | |
| 4 | 5 (16.6) | | | | |
| 5 = expert | 0 (0) | | | | |

^aReporting odds ratios (95% confidence intervals) and P values for dichotomous variables. Reporting beta coefficient (standard error) and P values for continuous variables.

NS, not significant; Gen Med, general medicine; NP, nurse practitioner.

Table 3

Interest in educational tools and programs to assist with a collection of cancer family history information and application of GC in clinical practice

| | | Statistically significant differences between clinical practice groups a | | | |
|--|--|---|------------------------------------|-------------------------------------|--|
| | Participant responses N (%) | Ob/Gyn vs. Gen Med and NPs | Gen Med vs. Ob/Gyn and NPs | NPs vs. Ob/Gyn and Gen Med | |
| | teractive educational tool (DVD, online in interpreting risk level and communic | | | | |
| Interest in tool for practitioners' use | | | | | |
| 1 = not at all interested | 14 (9.9) | NS | NS | NS | |
| 2 = somewhat interested | 37 (26.1) | | | | |
| 3 = interested | 49 (34.5) | | | | |
| 4 = very interested | 28 (19.7) | | | | |
| 5 = extremely interested | | | | | |
| Interest in tool for patients' use | | | | | |
| 1 = not at all interested | 14 (9.9) | NS | -0.6 (SE = 0.2); $P = 0.02$ | NS | |
| 2 = somewhat interested | 9 (6.5) | | | | |
| 3 = interested | 37 (26.6) | | | | |
| 4 = very interested | 48 (34.5) | | | | |
| 5 = extremely interested | 29 (20.9) | | | | |
| How important do you think using ge | netic counseling for cancer risk would l | be in your practice, if you fe | elt proficient in genetic cou | unseling? | |
| 1 = not at all important | 6 (4.3) | 0.7 (SE = 0.2); P = 0.0003 | -0.9 (SE = 0.2); <i>P</i> < 0.0001 | NS | |
| 2 = somewhat important | 47 (33.8) | | | | |
| 3 = important | 35 (25.2) | | | | |
| 4 = very important | 39 (28.1) | | | | |
| 5 = extremely important | 12 (8.6) | | | | |
| Would you apply genetic counseling to | for cancer risk in your current work sett | ing if you had the skills? | | | |
| Yes | 112 (84.9) | NS | NS | NS | |
| No | 20 (15.1) | | | | |
| What is your level of motivation to le | arn genetic counseling for cancer risk, i | if you had the opportunity? | | | |
| 1 = not at all motivated | 12 (8.6) | NS | -0.8 (SE = 0.2); P = 0.0002 | NS | |
| 2 = somewhat motivated | 47 (33.8) | | | | |
| 3 = motivated | 49 (35.2) | | | | |
| 4 = very motivated | 19 (13.7) | | | | |
| 5 = extremely motivated | 12 (8.6) | | | | |
| Would you be interested in attending (with continuing medical education or | a professional, no-cost 1–2-day training redits available)? | g workshop on genetic coun | seling for cancer risk | | |
| Yes | | 2.7 (1.1–6.6); <i>P</i> = 0.03 | NS | NS | |

| | Statistically significant differences between clinical practice groups a | | |
|-----------------------------|---|----------------------------------|-------------------------------------|
| Participant responses N (%) | Ob/Gyn vs. Gen Med and NPs | Gen Med vs. Ob/Gyn and NPs | NPs vs. Ob/Gyn and Gen Med |

aReporting odds ratios (95% confidence intervals) and P values for dichotomous variables. Reporting beta coefficient (standard error) and P values for continuous variables.

NS, not significant; Gen Med, general medicine; NP, nurse practitioner.